Its announcement arrives about the heels of the same licensing arrangement supplied in February to Adastra Labs, which had until eventually now centered on crafting cannabis extracts.The licensing deal comes after a radical policy change to address an opioid overdose crisis which has killed countless numbers, by decriminalizing smaller quantities